| Treatment groups |  | |||||||
---|---|---|---|---|---|---|---|---|---|
Tat 7.5 μg, 3x | Tat 7.5 μg, 5x | Tat 30 μg, 3x | Tat 30 μg, 5x | ||||||
 | N | % | N | % | N | % | N | % | Total |
Number of subjects in the safety population | 43 | Â | 44 | Â | 40 | Â | 41 | Â | 168 |
Number of subjects with at least one adverse event | 27 | 62.8 | 26 | 59.1 | 26 | 65.0 | 25 | 61.0 | 103 |
Serious adverse events | 2 | 7.14 | 2 | 7.1 | 3 | 11.1 | 3 | 11.1 | 10 |
Non-Serious Adverse Events | 26 | 92.9 | 26 | 92.9 | 24 | 88.9 | 24 | 88.9 | 100 |
Adverse Events leading to withdrawal | 1 | 1.3 | 2 | 2.5 | 2 | 2.6 | 2 | 2.9 | 7 |
Deaths | 0 | Â | 0 | Â | 0 | Â | 0 | Â | 0 |
Relationship with study medication | |||||||||
Certain | 3 | 8.6 | 3 | 8.6 | 4 | 12.5 | 8 | 23.5 | 18 |
Probable | 1 | 2.9 | 5 | 14.3 | 3 | 4.0 | 3 | 8.8 | 12 |
Possible | 4 | 11.5 | 3 | 8.6 | 4 | 12.5 | 2 | 5.9 | 13 |
Unlikely | 2 | 5.7 | 3 | 8.6 | 1 | 3.3 | 0 | 0.0 | 6 |
Unrelated | 25 | 71.4 | 21 | 60.0 | 20 | 62.5 | 21 | 61.8 | 87 |
Severity | |||||||||
Mild | 26 | 76.5 | 25 | 67.6 | 22 | 71.0 | 21 | 63.6 | 94 |
Moderate | 6 | 17.6 | 8 | 21.6 | 7 | 22.6 | 9 | 27.3 | 30 |
Severe | 2 | 5.9 | 4 | 10.8 | 2 | 6.4 | 3 | 9.1 | 11 |